Mitochondrial Inhibitors for ALS

NRG Therapeutics has secured £50 million to push its mitochondrial permeability transition pore inhibitors into human trials for amyotrophic lateral sclerosis (ALS) and Parkinson's disease. The drugs aim to keep the mitochondrial pore closed, preventing nerve cell death and slowing disease progression. For people with ALS, this work could slow the disease and offer new hope.